Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 828201, 5 pages
http://dx.doi.org/10.1155/2013/828201
Research Article

Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival

1Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka Street 59, 02-006 Warsaw, Poland
2Department of Anatomic Pathology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland
3Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland

Received 2 August 2013; Accepted 21 October 2013

Academic Editor: Basak Kayhan

Copyright © 2013 Michał Ciszek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ozawa, P. I. Terasaki, J. H. Lee et al., “14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis,” Tissue Antigens, vol. 69, supplement 1, pp. 174–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Kozlowski, K. Andreoni, J. Schmitz, P. H. Hayashi, and V. Nickeleit, “Sinusoidal C4d deposits in liver allografts indicate an antibody mediated response: diagnostic considerations in the evaluation of liver allografts,” Liver Transplantation, vol. 18, pp. 641–658, 2012. View at Google Scholar
  3. P. T. Donaldson, G. J. Alexander, J. O'Grady et al., “Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation,” The Lancet, vol. 1, no. 8539, pp. 945–951, 1987. View at Google Scholar · View at Scopus
  4. M. Castillo-Rama, M. J. Castro, I. Bernardo et al., “Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility,” Liver Transplantation, vol. 14, no. 4, pp. 554–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Watson, T. Kozlowski, V. Nickeleit et al., “Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation,” American Journal of Transplantation, vol. 6, no. 12, pp. 3022–3029, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Kozlowski, T. Rubinas, V. Nickeleit et al., “Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies,” Liver Transplantation, vol. 17, no. 4, pp. 357–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Zou, P. Stastny, C. Süsal, B. Döhler, and G. Opelz, “Antibodies against MICA antigens and kidney-transplant rejection,” New England Journal of Medicine, vol. 357, no. 13, pp. 1293–1300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lemy, M. Andrien, A. Lionet et al., “Posttransplant major histocompatibility complex class I chain-related gene a antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients,” Transplantation, vol. 93, pp. 1258–1264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Zou, X. Yang, X. Jiang et al., “High levels of soluble Major Histocompatibility Complex class I related chain A (MICA) are associated with biliary cast syndrome after liver transplantation,” Transplant Immunology, vol. 21, no. 4, pp. 210–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Uzunel, H. Kasimu, M. Joshi et al., “Evidence for no relevance of anti-major histocompatibility complex class I-related chain A antibodies in liver transplantation,” Liver Transplantation, vol. 14, no. 12, pp. 1793–1802, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Taner, M. J. Gandhi, S. O. Sanderson et al., “Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year,” American Journal of Transplantation, vol. 12, pp. 1504–1510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Neuhaus, P. Clavien, D. Kittur et al., “Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial,” Liver Transplantation, vol. 8, no. 2, pp. 132–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. Haddad, V. C. McAlister, E. Renouf, R. Malthaner, M. S. Kjaer, and L. L. Gluud, “Cyclosporin versus tacrolimus for liver transplanted patients,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005161, 2006. View at Google Scholar · View at Scopus
  14. A. I. Musat, R. M. Agni, P. Y. Wai et al., “The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation,” American Journal of Transplantation, vol. 11, no. 3, pp. 500–510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. O'Leary, H. Kaneku, B. M. Susskind et al., “High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant,” American Journal of Transplantation, vol. 11, no. 9, pp. 1868–1876, 2011. View at Publisher · View at Google Scholar · View at Scopus